Lasa Supergenerics Ltd
NSE:LASA

Watchlist Manager
Lasa Supergenerics Ltd Logo
Lasa Supergenerics Ltd
NSE:LASA
Watchlist
Price: 9.04 INR -1.2% Market Closed
Market Cap: ₹452.9m

Relative Value

LASA doesn't have a meaningful market cap.

The Relative Value of one LASA stock under the Base Case scenario is hidden INR. Compared to the current market price of 9.04 INR, Lasa Supergenerics Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LASA Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

LASA Competitors Multiples
Lasa Supergenerics Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Lasa Supergenerics Ltd
NSE:LASA
452.9m INR 0.5 -1.3 -54.1 -4.2
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.4 56.3 37.7 40.4
US
Johnson & Johnson
NYSE:JNJ
566.4B USD 6 21.1 14.7 18
CH
Roche Holding AG
SIX:ROG
287.9B CHF 4.7 30.7 12.9 15.1
US
Merck & Co Inc
NYSE:MRK
297.4B USD 4.6 15.6 11 13
CH
Novartis AG
SIX:NOVN
229.6B CHF 5.3 20.5 12.9 16.6
UK
AstraZeneca PLC
LSE:AZN
215B GBP 5.1 31.6 15.1 22.1
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.1 9.2 10.6
US
Pfizer Inc
NYSE:PFE
151.8B USD 2.4 15.5 7.8 10.7
FR
Sanofi SA
PAR:SAN
98.9B EUR 1.8 8.3 7.7 7.7
P/E Multiple
Earnings Growth PEG
IN
Lasa Supergenerics Ltd
NSE:LASA
Average P/E: 23.6
Negative Multiple: -1.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
56.3
54%
1
US
Johnson & Johnson
NYSE:JNJ
21.1
6%
3.5
CH
Roche Holding AG
SIX:ROG
30.7
29%
1.1
US
Merck & Co Inc
NYSE:MRK
15.6
14%
1.1
CH
Novartis AG
SIX:NOVN
20.5
17%
1.2
UK
AstraZeneca PLC
LSE:AZN
31.6
38%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
2%
6.6
US
Pfizer Inc
NYSE:PFE
15.5
27%
0.6
FR
Sanofi SA
PAR:SAN
8.3
1%
8.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Lasa Supergenerics Ltd
NSE:LASA
Average EV/EBITDA: 46.2
Negative Multiple: -54.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.7
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.7
2%
7.4
CH
Roche Holding AG
SIX:ROG
12.9
5%
2.6
US
Merck & Co Inc
NYSE:MRK
11
6%
1.8
CH
Novartis AG
SIX:NOVN
12.9
6%
2.1
UK
AstraZeneca PLC
LSE:AZN
15.1
10%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.2
1%
9.2
US
Pfizer Inc
NYSE:PFE
7.8
0%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Lasa Supergenerics Ltd
NSE:LASA
Average EV/EBIT: 99
Negative Multiple: -4.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.4
37%
1.1
US
Johnson & Johnson
NYSE:JNJ
18
6%
3
CH
Roche Holding AG
SIX:ROG
15.1
6%
2.5
US
Merck & Co Inc
NYSE:MRK
13
8%
1.6
CH
Novartis AG
SIX:NOVN
16.6
12%
1.4
UK
AstraZeneca PLC
LSE:AZN
22.1
23%
1
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
0%
N/A
US
Pfizer Inc
NYSE:PFE
10.7
7%
1.5
FR
Sanofi SA
PAR:SAN
7.7
6%
1.3